Difference between revisions of "Event:298"
From AOP-Wiki
(Updated summary tables from widget page.) |
(Updated summary tables from widget page.) |
||
Line 9: | Line 9: | ||
== Key Event Overview == | == Key Event Overview == | ||
− | Please follow link to [ | + | Please follow link to [//{{SERVERNAME}}/aopportal/events/{{PAGENAMEE}} widget page] to edit this section. |
=== AOPs Including This Key Event === | === AOPs Including This Key Event === | ||
Line 51: | Line 51: | ||
|} | |} | ||
+ | |||
== How this Key Event works == | == How this Key Event works == | ||
Revision as of 17:09, 11 January 2015
Contents
Event Title
Vascular, insufficiency
Short name: Vascular, insufficiency
Key Event Overview
Please follow link to widget page to edit this section.
AOPs Including This Key Event
AOP Name | Event Type | Essentiality |
---|---|---|
VEGFR2 Vascular Disruption and Adverse Developmental Outcomes | KE | Strong |
Taxonomic Applicability
Name | Scientific Name | Evidence | Links |
---|
Level of Biological Organization
Biological Organization |
---|
How this Key Event works
How it is Measured or Detected
Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?